About TearSolutions
TearSolutions is a Healthcare company based in Charlottesville (United States) founded in 2013. Topical therapeutics for the treatment of dry eye disease. TearSolutions has raised $44.07 million across 12 funding rounds from investors including Santen Pharmaceuticals, VTC Innovation Fund and Pharmstandard. TearSolutions offers products and services including Lacripep. Its focus areas include Life Sciences, Ophthalmology, Drugs and Dry-Eye Diseases. Its competitors include Oyster Point Pharmaceuticals, Retrotope and Lineage Cell Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.
- Headquarters Charlottesville, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website tearsolutions.com
- Social LinkedIn Facebook
- Total Equity Funding$44.07M (USD)
in 12 rounds
- Latest Funding Round$517K (USD), Series B
Oct 2025
- InvestorsSanten Pharmaceuticals
& 4 more
Products & Services of TearSolutions
TearSolutions offers a comprehensive portfolio of products and services, including Lacripep.
Topical treatment to restore tear film and heal ocular surfaces.
Funding Insights of TearSolutions
TearSolutions has successfully raised a total of $44.07M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $517 thousand completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.07M
- Total Rounds 12
- Last Round Series B β $517,000
- First Round $390,000
(Jun 2014)
- Investors Count 5
Latest 10 of 12 funding rounds of TearSolutions with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $517,000 | Series B | β | β | β |
| Sep 2024 | $12.71M | Series B | β | β | β |
| Sep 2023 | $390,000 | Series B | β | β | β |
| Jul 2021 | $5.62M | Series B | β | β | β |
| Feb 2020 | $1.5M | Series B | β | β | β |
| Apr 2019 | $6.45M | Series B | β | β | β |
| Dec 2017 | $8.5M | Series B | β | β | |
| May 2017 | $3.41M | Series A | β | β | β |
| Jan 2017 | $1.08M | Series B | β | β | β |
| Nov 2015 | $3M | Series A | β | β |
5 investors in total: 5 institutional.
Investors in TearSolutions
TearSolutions has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Santen Pharmaceuticals, VTC Innovation Fund and Pharmstandard.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| vtcinnovationfund.com | ||||
VC firm investing in seed & early stage companies in the US | launchcapital.com | New Haven, United States | ||
Early-stage VC firm funding companies in the US | cit.org | Herndon, United States | ||
Produces high-quality generic and biosimilar pharmaceutical products. | 2003 | pharmstd.com | Moscow, Russia | |
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured. | 1890 | santen.com | Osaka, Japan |
Investor details for TearSolutions
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TearSolutions
3 people are tracked at TearSolutions (3 in leadership).
| Name | Role | Group |
|---|---|---|
Colin M. Rolph | Chief Financial Officer | Leadership |
Anil Asrani | President and CEO | Leadership |
James Cook | Chief Development Officer | Leadership |
Complete people profiles for TearSolutions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TearSolutions
3 dated milestones of TearSolutions across 12 years, from founding to its latest funding, stage changes and deals.
- Founded TearSolutions is founded.
- Funding First funding round of $390K.
- Funding Latest funding round, Series B, of $517K.
Competitors of TearSolutions
TearSolutions has 3 listed competitors in our database, 3 of them funded. They include Oyster Point Pharmaceuticals, Retrotope and Lineage Cell Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| oysterpointrx.com | 2015 | Princeton, United States | $121.61M | 303 | Gene therapies for ophthalmological diseases are developed. | |
| retrotope.com | 2006 | Los Altos, United States | $58.58M | Therapeutics for neurodegenerative and ophthalmological diseases are developed. | ||
| lineagecell.com | 1990 | Carlsbad, United States | $45.8M | 75 | Lineage Cell Therapeutics is focused on developing allogeneic cell therapies. |
Detailed competitors of TearSolutions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TearSolutions
The website of TearSolutions (tearsolutions.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 17.4% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as TearSolutions (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tearsolutions
Complete news archive for TearSolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TearSolutions
TearSolutions was founded in 2013 and raised its 1st funding round 1 year after it was founded.
TearSolutions is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
TearSolutions is a funded company, having raised a total of $44.07M across 12 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Jun 2014.
TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.
TearSolutions's top competitors include Lineage Cell Therapeutics, Oyster Point Pharmaceuticals and Retrotope.
TearSolutions offers Lacripep.
TearSolutions has 5 investors. Key investors include Santen Pharmaceuticals, VTC Innovation Fund, Pharmstandard, LaunchCapital, and Center for Innovative Technology.